From 6 till 10 December 2022: HIGHLIGHTS ON BREAST CANCER

Your direct line with San Antonio

The San Antonio Breast Cancer Symposium (SABCS) is in its 45th year, and a lot of breast cancer research news is coming up. The MediMix team is onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen.

And, we dive into posters and hot topics with the experts as they are being presented.

Stay tuned!

With the support of Eli Lilly Benelux & Daiichi-Sankyo | AstraZeneca

Daily highlights

“Top Stories” from SABCS 2022

At the end of the San Antonio breast cancer symposium, Belgian experts were asked to compile a top three of the most important presentations. Unanimously chosen was the POSITIVE study, which showed that it is safe to temporarily interrupt adjuvant endocrine treatment in pregnancy. The DESTINY Breast02 study was also

See video »

Day 5: Therapeutic strategies in the neoadjuvant setting

In the last general session of this year’s San Antonio breast cancer symposium, prof François Duhoux from the university hospital Saint Luc, Brussels, gave an excellent summary of five exciting topics. Firstly, he discussed a phase 3 trial where platinum was added to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with

See video »
dr. Kristof Van Berckelaer

Day 4: Highlights in early breast cancer

Day 4 at the San Antonio Breast Cancer Symposium (SABCS) is summarised here by Dr Kristof Van Berckelaer, gynaecologist at the University Hospital Antwerp. He presented results from the prospective ACOSOG Z11102 phase 2 trial evaluating the impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral

See video »

Day 2: New data on the use of trastuzumab deruxtecan

Day 2 at the San Antonio Breast Cancer Symposium (SABCS) 2022 focused on new data on the use of trastuzumab deruxtecan. The updated survival results of the DESTINY-Breast03 study were presented, as well as outcomes of trastuzumab deruxtecan in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with

See video »

Day 1: Luminal Breast Cancer in the picture

It’s the first day at the San Antonio Breast Cancer Symposium (SABCS) 2022. And at this first day, Luminal Breast Cancer is the topic of the first general session, with exciting presentations both in primary and metastatic breast cancer. MediMix asked Prof Hans Wildiers from the University Hospital Gasthuisberg, KU

See video »

Project in the spotlight

The Uptider Project

At the San Antonio Breast Cancer Symposium, a Belgian poster caught our particular attention. Therefore, we are happy to place the project in the spotlight. Uptider is KU Leuven project for post-mortem tissue donation in breast cancer patients, to gain more insight into the evolutionary biology of metastatic breast cancer. In this video you hear and see everything about the project.

See video »

In-depth stories

Prof. Dr. Per Karlsson

Validation of profile for the omission of local adjuvant radiotherapy (POLAR) in a meta-analysis of three randomized controlled trials of breast conserving surgery +/- radiotherapy

The POLAR signature is a genetic classifier to define benefit of breast cancer radiotherapy. In this interview prof. dr. Per Karlsson from the Sahlgrenska Academy, Gothenburg, Sweden explained how clinical validation was performed via a patient-level meta-analysis of node-negative patients with ER+ / HER2-tumors from 3 clinical trials. The performance of the POLAR signature as a prognostic factor for locoregional recurrence in the absence of RT and as a predictor of benefit from radiotherapy following breast conserving surgery, was evaluated. He concludes with a glimpse into the future.

See video »

Update of the monarchE trial with abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer

The 4-year follow up data of a pre-planned overall survival analysis of the monarchE trial were presented at SABCS as an oral presentation and are simultaneously published in The Lancet Oncology. Prof dr Patrick Neven from UZ Leuven, one of the co-authors of the monarchE trial, took the time to put the recent data in perspective. Besides explaining the clinically meaningful benefit, guidance on managing potential side effects is also given.  

See video »

Poster selection

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy